SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week
wash out period.
Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in
overweight/obese patients with CFRD to support a future larger randomized controlled trial.